| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $34.1M | — | -15.9% |
| SG&A Expense | $17.4M | — | +31.0% |
| Operating Income | -$50.7M | — | +3.3% |
| Net Income | -$49.1M | — | +5.3% |
| EPS (Basic) | -$0.28 | — | +30.0% |
| EPS (Diluted) | -$0.28 | — | +30.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $64.1M | +1.7% | -30.2% |
| Current Assets | $137.9M | -23.9% | -15.8% |
| Total Assets | $294.7M | -14.0% | -10.2% |
| Current Liabilities | $36.3M | -3.1% | +5.8% |
| Total Liabilities | $218.0M | -1.7% | -1.5% |
| Stockholders' Equity | $76.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$42.7M | — | +12.6% |
| Capital Expenditures | $214K | — | -91.2% |
| Investing Cash Flow | $43.4M | — | +190.9% |
| Financing Cash Flow | $393K | — | -93.5% |
| Free Cash Flow | -$42.9M | — | +16.3% |
| -28.3% |